Ultragenyx Pharmaceutical Inc. (RARE) Expected to Earn FY2018 Earnings of ($6.88) Per Share

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Jefferies Group reduced their FY2018 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report issued on Monday. Jefferies Group analyst M. Raycroft now forecasts that the biopharmaceutical company will earn ($6.88) per share for the year, down from their prior forecast of ($6.67). Jefferies Group currently has a “Buy” rating and a $72.00 target price on the stock. Jefferies Group also issued estimates for Ultragenyx Pharmaceutical’s FY2019 earnings at ($6.43) EPS, FY2020 earnings at ($4.94) EPS and FY2021 earnings at ($2.12) EPS.

Other equities analysts have also issued reports about the company. Stifel Nicolaus reissued a “buy” rating and issued a $85.00 price target (down from $95.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Leerink Swann reissued an “outperform” rating and issued a $83.00 price target (down from $89.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. JMP Securities dropped their price target on Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 23rd. Barclays boosted their price target on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Tuesday. Finally, Canaccord Genuity set a $80.00 price target on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $72.40.

Shares of Ultragenyx Pharmaceutical (RARE) traded down $1.18 on Wednesday, reaching $48.78. The company’s stock had a trading volume of 534,000 shares, compared to its average volume of 438,441. Ultragenyx Pharmaceutical has a 12-month low of $44.02 and a 12-month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.87). The business had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.02 million. During the same period last year, the firm posted ($1.64) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% compared to the same quarter last year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RARE. Dimensional Fund Advisors LP grew its holdings in Ultragenyx Pharmaceutical by 51.6% during the first quarter. Dimensional Fund Advisors LP now owns 17,092 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 5,816 shares in the last quarter. Aperio Group LLC grew its holdings in Ultragenyx Pharmaceutical by 8.4% during the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 299 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Ultragenyx Pharmaceutical by 11.4% during the second quarter. Russell Investments Group Ltd. now owns 31,184 shares of the biopharmaceutical company’s stock worth $1,937,000 after buying an additional 3,195 shares in the last quarter. Sei Investments Co. bought a new stake in Ultragenyx Pharmaceutical during the second quarter worth $125,000. Finally, TD Asset Management Inc. grew its holdings in Ultragenyx Pharmaceutical by 4.4% during the second quarter. TD Asset Management Inc. now owns 37,728 shares of the biopharmaceutical company’s stock worth $2,343,000 after buying an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 94.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/12/07/ultragenyx-pharmaceutical-inc-rare-expected-to-earn-fy2018-earnings-of-6-88-per-share.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply